# LMO3

## Overview
LMO3 (LIM domain only 3) is a gene that encodes a protein involved in transcriptional regulation, primarily through its role in protein-protein interactions within the nucleus. The LMO3 protein is characterized by the presence of LIM domains, which are zinc finger-like structures that facilitate these interactions, allowing it to form complexes with other transcription factors and influence gene expression. This protein is predominantly expressed in the brain and fetal brain, suggesting a significant role in neuronal development and function. LMO3 is implicated in various cellular processes, including cell fate determination and differentiation during embryonic development, and has been associated with oncogenic activities in several cancers, such as neuroblastoma and hepatocellular carcinoma. Its interactions with other proteins, such as HEN2 and LATS1, underscore its potential as a therapeutic target in cancer treatment (Cheng2018LMO3; Aoyama2005LMO3).

## Function
LMO3 (LIM domain only 3) is a gene that encodes a protein involved in transcriptional regulation, primarily active in the nucleus. The LMO3 protein contains LIM domains, which are zinc finger-like structures that facilitate protein-protein interactions, allowing it to form complexes with other transcription factors and influence gene expression (Aoyama2005LMO3). In healthy human cells, LMO3 is predominantly expressed in the brain and fetal brain, with lower levels in the heart and lung, indicating a role in neuronal development and function (Aoyama2005LMO3).

LMO3 interacts with various transcription factors, such as HEN2, and nuclear LIM domain-binding proteins like Ldb1 and Ldb2, which are involved in transcriptional regulation processes (Aoyama2005LMO3). This interaction suggests that LMO3 plays a role in cell fate determination and differentiation during embryonic development, similar to other members of the LIM-only protein family (Aoyama2005LMO3). The protein's activity in the nucleus and its ability to form transcriptional complexes highlight its importance in regulating gene expression, which is crucial for proper cellular function and development.

## Clinical Significance
Alterations in the expression of the LMO3 gene have been implicated in several cancers. In neuroblastoma, LMO3 acts as an oncogene, with higher expression levels associated with aggressive tumors and poor prognosis. LMO3 interacts with the neuronal transcription factor HEN2, promoting tumor growth and progression (Aoyama2005LMO3). The gene's expression is particularly elevated in neuroblastomas with MYCN amplification, although LMO3 and HEN2 are not direct downstream targets of MYCN (Aoyama2005LMO3).

In hepatocellular carcinoma (HCC), LMO3 is significantly upregulated, promoting invasion, metastasis, and anoikis inhibition. It interacts with LATS1, suppressing the Hippo signaling pathway, which is crucial for controlling cell proliferation and apoptosis (Cheng2018LMO3). This upregulation is associated with poor overall survival in HCC patients (Cheng2018LMO3).

LMO3 is also involved in lung adenocarcinoma, where it is a transcriptional target of the NKX2-1 gene. Its expression is essential for the proliferation and survival of NKX2-1-amplified lung adenocarcinoma cell lines, contributing to the pathogenesis of this cancer (Watanabe2013Integrated).

In prostate cancer, lower LMO3 expression is linked to unfavorable progression-free and disease-free survival, suggesting its potential as a prognostic biomarker (Xu2022LMO3).

## Interactions
LMO3, a member of the LIM-only protein family, is involved in several protein-protein interactions that are significant in various cancers. In neuroblastoma, LMO3 interacts with the neuronal transcription factor HEN2. This interaction occurs in the nucleus of mammalian cells and is associated with increased cell growth and tumor progression, indicating LMO3's oncogenic potential in this cancer type (Aoyama2005LMO3). 

In hepatocellular carcinoma (HCC), LMO3 interacts with Large Tumor Suppressor Kinase 1 (LATS1), a component of the Hippo signaling pathway. This interaction suppresses the phosphorylation of YAP and LATS1, promoting cancer cell invasion and metastasis (Cheng2018LMO3). 

LMO3 also interacts with the calcium- and integrin-binding protein (CIB) through its second LIM domain. This interaction results in the translocation of LMO3 from the nucleus to the cytoplasm and inhibits cell proliferation, suggesting a regulatory role of CIB in LMO3-mediated cell growth (Hui2009The). 

These interactions highlight LMO3's role in modulating cellular processes and its potential as a therapeutic target in cancer treatment.


## References


[1. (Hui2009The) Ling Hui, Chaoneng Ji, Bin Hui, Tongde Lv, Xiaoqin Ha, Jinsheng Yang, and Wenqin Cai. The oncoprotein lmo3 interacts with calcium- and integrin-binding protein cib. Brain Research, 1265:24–29, April 2009. URL: http://dx.doi.org/10.1016/j.brainres.2009.02.021, doi:10.1016/j.brainres.2009.02.021. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.brainres.2009.02.021)

[2. (Xu2022LMO3) Wenchao Xu, Taotao Sun, Jiaxin Wang, Hao Li, Bingliang Chen, Yingjian Zhou, Tao Wang, Shaogang Wang, Jihong Liu, and Hongyang Jiang. Lmo3 downregulation in pca: a prospective biomarker associated with immune infiltration. Frontiers in Genetics, September 2022. URL: http://dx.doi.org/10.3389/fgene.2022.945151, doi:10.3389/fgene.2022.945151. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.945151)

[3. (Cheng2018LMO3) Yang Cheng, Tianlu Hou, Jian Ping, Tianyang Chen, and Baobing Yin. Lmo3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with lats1 and suppressing hippo signaling. Journal of Experimental &amp; Clinical Cancer Research, September 2018. URL: http://dx.doi.org/10.1186/s13046-018-0903-3, doi:10.1186/s13046-018-0903-3. This article has 29 citations.](https://doi.org/10.1186/s13046-018-0903-3)

[4. (Aoyama2005LMO3) Mineyoshi Aoyama, Toshinori Ozaki, Hiroyuki Inuzuka, Daihachiro Tomotsune, Junko Hirato, Yoshiaki Okamoto, Hisashi Tokita, Miki Ohira, and Akira Nakagawara. Lmo3 interacts with neuronal transcription factor, hen2, and acts as an oncogene in neuroblastoma. Cancer Research, 65(11):4587–4597, June 2005. URL: http://dx.doi.org/10.1158/0008-5472.can-04-4630, doi:10.1158/0008-5472.can-04-4630. This article has 93 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-04-4630)

[5. (Watanabe2013Integrated) Hideo Watanabe, Joshua M. Francis, Michele S. Woo, Banafsheh Etemad, Wenchu Lin, Daniel F. Fries, Shouyong Peng, Eric L. Snyder, Purushothama Rao Tata, Francesca Izzo, Anna C. Schinzel, Jeonghee Cho, Peter S. Hammerman, Roel G. Verhaak, William C. Hahn, Jayaraj Rajagopal, Tyler Jacks, and Matthew Meyerson. Integrated cistromic and expression analysis of amplified nkx2-1 in lung adenocarcinoma identifies lmo3 as a functional transcriptional target. Genes &amp; Development, 27(2):197–210, January 2013. URL: http://dx.doi.org/10.1101/gad.203208.112, doi:10.1101/gad.203208.112. This article has 58 citations.](https://doi.org/10.1101/gad.203208.112)